Rx Pricing At The High Court: Justices Friendlier To Enforcement From States Than 340B Entities

U.S. Supreme Court justices’ skepticism over the right of 340B entities to sue pharmaceutical companies for overcharges does not appear to extend to states’ ability to challenge drug prices reported under Medicaid.